For each variant, its arsenal of treatments and monoclonal antibodies. Molecules similar to human antibodies but made by gene therapy, the latter aim to reduce the risk of hospitalization and the severity of the disease, provided they are taken within seven days of the onset of symptoms. These treatments are intended, as a priority, for patients who are immunocompromised due to leukemia, a kidney transplant or in particular AIDS. But with each variant, the question of their effectiveness rests. After the fall of the Alpha variant in favor of Delta, the panoply of drugs had already been rethought: Roche's dual therapy had replaced that of the Eli Lilly group, which was no longer effective. Now both are overtaken by the surge of the Omicron variant.
Read also
After the emergence of the Delta variant, Roche's monoclonal antibodies replaced those of Eli Lilly in the hospital
In record time after its detection, at the end of November in South Africa, scientists from the Institut Pasteur in Paris associated with those from KU Leuven (Belgium) estimated, in a pre-published article on BioRxiv…
This article is for subscribers only.
You have 66% left to discover.
Pushing back the limits of science is also freedom.
Continue reading your article for € 1 the first month
I ENJOY IT
Already subscribed?
Log in
